Radioactive drug combo shows promise for advanced prostate cancer
NCT ID NCT03361735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of radium-223 (a radioactive drug that targets bone tumors), hormone therapy, and precise radiation for men with prostate cancer that has spread to a few other places in the body. The goal is to see if this triple approach can delay cancer progression better than standard treatments. The study enrolled 25 participants and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radium Ra 223 dichloride (a radioactive drug that targets bone tumors)
What this could lead to
If successful, this combination could offer a new way to delay cancer progression in men with prostate cancer that has spread to a few spots in the body.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The treatment involves radiation and hormone therapy, which can cause side effects like fatigue, bone pain, and hormonal changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States